From genotype to phenotype: Early prediction of disease severity in argininosuccinic aciduria.
Adolescent
Adult
Argininosuccinate Lyase
/ blood
Argininosuccinic Aciduria
/ diagnosis
Biomarkers
Child
Child, Preschool
Enzyme Activation
Female
Gene Expression
Genetic Association Studies
/ methods
Genetic Predisposition to Disease
Genotype
Humans
Kidney
/ metabolism
Liver
/ metabolism
Male
Middle Aged
Mutation
Phenotype
RNA, Messenger
/ genetics
Severity of Illness Index
Young Adult
argininosuccinic aciduria
clinical outcome
disease course
enzymatic ASL activity
predictive biomarker
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
07
10
2019
revised:
29
11
2019
accepted:
10
01
2020
pubmed:
17
1
2020
medline:
22
7
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
Argininosuccinic aciduria (ASA) is an inherited urea cycle disorder and has a highly variable phenotypic spectrum ranging from individuals with lethal hyperammonemic encephalopathy, liver dysfunction, and cognitive deterioration, to individuals with a mild disease course. As it is difficult to predict the phenotypic severity, we aimed at identifying a reliable disease prediction model. We applied a biallelic expression system to assess the functional impact of pathogenic argininosuccinate lyase (ASL) variants and to determine the enzymatic activity of ASL in 58 individuals with ASA. This cohort represented 42 ASL gene variants and 42 combinations in total. Enzymatic ASL activity was compared with biochemical and clinical endpoints from the UCDC and E-IMD databases. Enzymatic ASL activity correlated with peak plasma ammonium concentration at initial presentation and with the number of hyperammonemic events (HAEs) per year of observation. Individuals with ≤9% of enzymatic activity had more severe initial decompensations and a higher annual frequency of HAEs than individuals above this threshold. Enzymatic ASL activity also correlated with the cognitive outcome and the severity of the liver disease, enabling a reliable severity prediction for individuals with ASA. Thus, enzymatic activity measured by this novel expression system can serve as an important marker of phenotypic severity.
Identifiants
pubmed: 31943503
doi: 10.1002/humu.23983
pmc: PMC7428858
mid: NIHMS1069391
doi:
Substances chimiques
Biomarkers
0
RNA, Messenger
0
Argininosuccinate Lyase
EC 4.3.2.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
946-960Subventions
Organisme : NICHD NIH HHS
ID : P50 HD103555
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD061221
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD083092
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090257
Pays : United States
Investigateurs
Nicholas Ah Mew
(N)
Lindsay C Burrage
(LC)
Andreas Schulze
(A)
Susan A Berry
(SA)
Matthias R Baumgartner
(MR)
George A Diaz
(GA)
J Lawrence Merritt
(JL)
Jirair K Bedoyan
(JK)
Derek Wong
(D)
Cary O Harding
(CO)
Marc Yudkoff
(M)
Angeles Garcia-Cazorla
(A)
Elisenda Cortès-Saladelafont
(E)
Allan M Lund
(AM)
Carlo Dionisi-Vici
(C)
Alberto B Burlina
(AB)
Andrew A Morris
(AA)
Peter Freisinger
(P)
Magdalena E Walter
(ME)
Anil Jalan
(A)
Manuel Schiff
(M)
Dries Dobbelaere
(D)
Annet M Bosch
(AM)
Harikleia Ioannou
(H)
Ivo Barić
(I)
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Proc Natl Acad Sci U S A. 1984 Jul;81(14):4480-4
pubmed: 6589607
Ann Neurol. 2019 Jul;86(1):116-128
pubmed: 31018246
Exp Neurol. 2019 Apr;314:91-99
pubmed: 30653968
J Inherit Metab Dis. 2016 Jul;39(4):573-84
pubmed: 27215558
Nat Commun. 2018 Aug 29;9(1):3505
pubmed: 30158522
J Inherit Metab Dis. 2019 Nov;42(6):1147-1161
pubmed: 30723942
Orphanet J Rare Dis. 2011 Jun 20;6:44
pubmed: 21689452
Mol Genet Metab. 2018 Nov;125(3):235-240
pubmed: 30197275
J Biol Chem. 1997 Mar 7;272(10):6777-83
pubmed: 9045711
J Inherit Metab Dis. 2017 May;40(3):357-368
pubmed: 28251416
Am J Med Genet C Semin Med Genet. 2011 Feb 15;157C(1):45-53
pubmed: 21312326
Mol Genet Metab. 2010 May;100(1):24-8
pubmed: 20236848
Nat Med. 2011 Nov 13;17(12):1619-26
pubmed: 22081021
Ann Clin Transl Neurol. 2019 Sep;6(9):1858-1871
pubmed: 31469252
Stat Med. 1989 Apr;8(4):431-40
pubmed: 2727467
J Inherit Metab Dis. 2015 Nov;38(6):1059-74
pubmed: 25875216
J Inherit Metab Dis. 2015 Nov;38(6):1041-57
pubmed: 25875215
NeuroRx. 2004 Apr;1(2):189-95
pubmed: 15717019
J Inherit Metab Dis. 2019 Mar;42(2):243-253
pubmed: 30671983
Genet Med. 2019 Sep;21(9):1987-1997
pubmed: 30723321
Mol Genet Metab. 2014 Sep-Oct;113(1-2):127-30
pubmed: 25135652
Nephrol Dial Transplant. 2016 May;31(5):798-806
pubmed: 26932693
Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):668-675
pubmed: 29247835
Mol Genet Metab. 2018 Nov;125(3):241-250
pubmed: 30253962
Arch Biochem Biophys. 2014 Aug;555-556:16-22
pubmed: 24878366
J Pediatr. 2014 Apr;164(4):720-725.e6
pubmed: 24485820
Neurology. 2016 Mar 8;86(10):890-7
pubmed: 26865511
J Inherit Metab Dis. 2019 Jan;42(1):93-106
pubmed: 30740724
J Inherit Metab Dis. 2016 Mar;39(2):219-29
pubmed: 26634836
PLoS One. 2018 Sep 10;13(9):e0203707
pubmed: 30199544